edoc

COVID-19 vaccination in mastocytosis: recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)

Bonadonna, Patrizia and Brockow, Knut and Niedoszytko, Marek and Elberink, Hanneke Oude and Akin, Cem and Nedoszytko, Boguslaw and Butterfield, Joseph H. and Alvarez-Twose, Ivan and Sotlar, Karl and Schwaab, Juliana and Jawhar, Mohamad and Castells, Mariana and Sperr, Wolfgang R. and Hermine, Olivier and Gotlib, Jason and Zanotti, Roberta and Reiter, Andreas and Broesby-Olsen, Sigurd and Bindslev-Jensen, Carsten and Schwartz, Lawrence B. and Horny, Hans-Peter and Radia, Deepti and Triggiani, Massimo and Sabato, Vito and Carter, Melody C. and Siebenhaar, Frank and Orfao, Alberto and Grattan, Clive and Metcalfe, Dean D. and Arock, Michel and Gulen, Theo and Hartmann, Karin and Valent, Peter. (2021) COVID-19 vaccination in mastocytosis: recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM). The Journal of Allergy and Clinical Immunology. In Practice, 9 (6). pp. 2139-2144.

Full text not available from this repository.

Official URL: https://edoc.unibas.ch/82710/

Downloads: Statistics Overview

Abstract

Mastocytosis is a neoplasm characterized by an accumulation of mast cells in various organs and increased risk for severe anaphylaxis in patients with concomitant allergies. Covid-19 is a pandemic that is associated with a relatively high rate of severe lung disease and mortality. The mortality is particularly high in those with certain comorbidities and increases with age. Recently, several companies have developed an effective vaccination against Covid-19. Although the reported frequency of severe side effects is low, there is an emerging discussion about the safety of Covid-19 vaccination in patients with severe allergies and mastocytosis. However, even in these patients, severe adverse reactions are rare. We therefore recommend the broad use of Covid-19 vaccination in patients with mastocytosis on a global basis. The only well-established exception is a known or suspected allergy against a constituent of the vaccine. Safety measures, including premedication and post-vaccination observation should be considered in all patients with mastocytosis, depending on the individual personal risk and overall situation in each case. The current article provides a summary of published data, observations and expert opinion that form the basis of these recommendations.
Faculties and Departments:03 Faculty of Medicine > Bereich Spezialf├Ącher (Klinik) > Dermatologie USB > Allergologie (Hartmann)
03 Faculty of Medicine > Departement Klinische Forschung > Bereich Spezialf├Ącher (Klinik) > Dermatologie USB > Allergologie (Hartmann)
03 Faculty of Medicine > Departement Biomedizin > Department of Biomedicine, University Hospital Basel > Allergy and Immunity (Hartmann)
UniBasel Contributors:Hartmann, Karin
Item Type:Article, refereed
Article Subtype:Research Article
Publisher:Elsevier
ISSN:2213-2201
Note:Publication type according to Uni Basel Research Database: Journal article
Identification Number:
Last Modified:28 Jan 2022 15:27
Deposited On:28 Jan 2022 15:27

Repository Staff Only: item control page